211 results on '"KIEFER, James R."'
Search Results
2. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
3. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
4. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
5. Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model
6. Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
7. Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site
8. Water molecules in protein–ligand interfaces. Evaluation of software tools and SAR comparison
9. Structural basis for dual-mode inhibition of the ABC transporter MsbA
10. Post-translational regulation of RORγt—A therapeutic target for the modulation of interleukin-17-mediated responses in autoimmune diseases
11. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
12. Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
13. Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging
14. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
15. Molecular Basis for Cyclooxygenase Inhibition by the Non-steroidal Anti-inflammatory Drug Naproxen
16. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain
17. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
18. Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
19. Target 2035 – update on the quest for a probe for every protein
20. Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging.
21. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
22. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
23. High Resolution Crystal Structure of the Catalytic Domain of ADAMTS-5 (Aggrecanase-2)
24. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
25. Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
26. Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
27. Structure analysis reveals the flexibility of the ADAMTS-5 active site
28. Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity
29. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
30. Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer
31. Structural insights into the stereochemistry of the cyclooxygenase reaction
32. Visualizing DNA replication in a catalytically active Bacillus, DNA polymerase crystal
33. Observing Translesion Synthesis of an Aromatic Amine DNA Adduct by a High-fidelity DNA Polymerase
34. A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385
35. Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity
36. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
37. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance
38. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
39. Target 2035 – update on the quest for a probe for every protein
40. Cyclooxygenase enzymes: catalysis and inhibition
41. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors
42. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies
43. Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist
44. Structural basis for antagonism of bacterial LPS transport
45. Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
46. GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)
47. A reversed sulfonamide series of selective RORc inverse agonists
48. Improved Crystallographic Structures Using Extensive Combinatorial Refinement
49. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300
50. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.